tiprankstipranks
Advertisement
Advertisement

IKT Stock Latest News

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
Company AnnouncementsInhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
11d ago
IKT
Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)
PremiumThe Fly
Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)
12d ago
IKT
Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
PremiumRatings
Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
23d ago
IKT
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
PremiumCompany Announcements
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
25d ago
8K
IKT
Inhibikase Gains FDA Orphan Drug Status for IKT-001
PremiumCompany Announcements
Inhibikase Gains FDA Orphan Drug Status for IKT-001
1M ago
8K
IKT
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
PremiumThe FlyInhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
1M ago
IKT
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
Premium
The Fly
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
1M ago
IKT
Inhibikase raises $50M to fund PAH program
Premium
Company Announcements
Inhibikase raises $50M to fund PAH program
1M ago
8K
IKT
Inhibikase Shareholders Approve Governance and Compensation Changes
PremiumCompany Announcements
Inhibikase Shareholders Approve Governance and Compensation Changes
2M ago
8K
IKT
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
2M ago
IKT
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
PremiumRatings
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
3M ago
IKT
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
PremiumCompany Announcements
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
3M ago
IKT
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
PremiumCompany AnnouncementsInhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
3M ago
IKT
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
Premium
Ratings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
5M ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
Premium
Ratings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
5M ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
PremiumCompany Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
5M ago
8K
IKT
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
PremiumThe Fly
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
5M ago
IKT
IKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IKT Upcoming Earnings Report: What to Expect?
5M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
6M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe FlyInhibikase Therapeutics initiated with a Buy at Ladenburg
6M ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
Premium
Ratings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
6M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
Premium
Market News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
6M ago
IKT
WVE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >